Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Income Statement
Quarterly Data

Biogen Inc., consolidated income statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Product, net 1,962,100 2,054,900 2,066,300 2,193,500 2,205,700 2,236,000 2,211,700 2,301,600 2,690,300 2,795,700 2,904,600 2,924,800 2,894,700 2,880,300 2,680,000 2,825,700 2,780,100 2,757,500 2,523,500 2,712,400 2,622,500 2,639,700 2,380,100
Revenues from anti-CD20 therapeutic programs 416,900 436,300 399,400 414,100 415,400 440,000 389,000 419,000 560,100 478,300 520,400 600,800 595,800 576,400 517,400 534,900 511,700 490,400 443,200 415,000 406,500 397,100 340,600
Other 129,500 97,900 66,100 126,200 157,800 99,000 93,300 132,000 125,700 407,600 109,300 145,700 109,600 160,000 292,400 165,700 147,200 108,600 164,400 179,600 48,800 41,600 90,000
Revenue 2,508,500 2,589,100 2,531,800 2,733,800 2,778,900 2,775,000 2,694,000 2,852,600 3,376,100 3,681,600 3,534,300 3,671,300 3,600,100 3,616,700 3,489,800 3,526,300 3,439,000 3,356,500 3,131,100 3,307,000 3,077,800 3,078,400 2,810,700
Cost of sales, excluding amortization and impairment of acquired intangible assets (469,500) (484,000) (753,900) (660,100) (511,800) (459,700) (478,100) (490,700) (449,100) (411,100) (454,300) (447,100) (430,000) (476,300) (602,000) (488,500) (460,800) (421,000) (446,000) (509,200) (370,000) (366,200) (384,600)
Gross profit 2,039,000 2,105,100 1,777,900 2,073,700 2,267,100 2,315,300 2,215,900 2,361,900 2,927,000 3,270,500 3,080,000 3,224,200 3,170,100 3,140,400 2,887,800 3,037,800 2,978,200 2,935,500 2,685,100 2,797,800 2,707,800 2,712,200 2,426,100
Research and development (549,200) (528,600) (551,700) (699,500) (702,400) (585,100) (514,200) (1,726,100) (1,140,900) (647,600) (476,300) (691,700) (540,400) (484,800) (563,700) (611,600) (507,900) (981,000) (496,700) (587,600) (446,400) (796,200) (423,400)
Selling, general and administrative (563,300) (572,600) (634,900) (787,900) (654,100) (637,300) (595,000) (806,200) (573,100) (555,100) (570,100) (664,900) (554,500) (587,600) (567,700) (591,100) (497,700) (516,200) (501,300) (572,400) (433,800) (430,200) (499,100)
Amortization and impairment of acquired intangible assets (56,500) (67,500) (66,900) (68,100) (111,000) (604,100) (98,100) (249,200) (82,600) (61,500) (71,500) (67,700) (283,900) (70,100) (68,200) (254,100) (281,900) (107,400) (103,900) (139,800) (108,900) (117,500) (448,500)
Collaboration (profit) loss sharing (45,300) (29,400) 117,300 67,300 (21,200) 15,200 (68,500) (66,300) (73,000) (21,800) (71,800) (59,800) (60,200) (63,500) (58,100) (55,800) (47,500) (39,200) (42,500) (29,800) (35,200) (26,500) (20,800)
Gain (loss) on divestiture of Hillerød, Denmark manufacturing operations 92,500 40,200 17,700 2,300 (115,500)
Gain (loss) on fair value remeasurement of contingent consideration 2,100 4,500 7,100 1,600 15,600 (300) 33,800 62,700 29,000 (10,000) 4,600 (2,600) 57,800 20,000 (11,500) (79,300) 87,900 (1,900) 5,600 (1,500) (30,000) (21,200) (10,000)
Acquired in-process research and development (18,000) (75,000) (27,500) (75,000) (10,000) (120,000)
Restructuring charges (15,400) (70,600) (38,100) (300) (800) (400) (2,800) (6,000) (1,600) (1,600) (900)
Gain on sale of building 503,700
Income from operations 1,315,100 840,900 610,700 587,100 794,000 485,700 973,900 (330,700) 1,086,400 1,974,500 1,819,900 1,777,700 1,806,300 1,955,900 1,502,700 1,443,100 1,697,600 1,213,200 1,534,700 1,465,800 1,653,500 1,200,600 1,024,300
Other income (expense), net 56,000 428,600 (263,300) (182,100) (502,900) 96,400 (506,900) 683,500 (128,600) 63,000 (120,500) (49,300) (27,300) (197,400) 357,300 (28,600) 115,100 (34,500) (41,000) (66,000) (43,600) (68,200) (37,600)
Income before equity in income (loss) of investee and income tax (expense) benefit 1,371,100 1,269,500 347,400 405,000 291,100 582,100 467,000 352,800 957,800 2,037,500 1,699,400 1,728,400 1,779,000 1,758,500 1,860,000 1,414,500 1,812,700 1,178,700 1,493,700 1,399,800 1,609,900 1,132,400 986,700
Equity in income (loss) of investee, net of tax 5,900 (3,300) 17,700 1,100 34,300 (18,200) 18,100 (13,100) 15,100 (14,800) (12,600) (21,800) (16,300) (28,700)
Income before income tax (expense) benefit 1,371,100 1,275,400 344,100 422,700 292,200 616,400 448,800 370,900 944,700 2,052,600 1,684,600 1,715,800 1,757,200 1,742,200 1,831,300 1,414,500 1,812,700 1,178,700 1,493,700 1,399,800 1,609,900 1,132,400 986,700
Income tax (expense) benefit (236,200) (216,700) (125,600) (443,300) 25,900 409,100 (44,200) (13,400) (240,800) (446,100) (292,000) (276,100) (211,300) (248,100) (422,500) (469,600) (369,800) (263,700) (322,500) (1,566,100) (383,800) (269,600) (239,200)
Net income 1,134,900 1,058,700 218,500 (20,600) 318,100 1,025,500 404,600 357,500 703,900 1,606,500 1,392,600 1,439,700 1,545,900 1,494,100 1,408,800 944,900 1,442,900 915,000 1,171,200 (166,300) 1,226,100 862,800 747,500
Net (income) loss attributable to noncontrolling interests, net of tax (200) (700) 85,300 388,800 11,100 (577,000) 5,600 400 (2,400) (64,400) 6,500 1,900 1,500 (48,400) 1,700 (131,100) 100
Net income attributable to Biogen Inc. 1,134,700 1,058,000 303,800 368,200 329,200 448,500 410,200 357,900 701,500 1,542,100 1,399,100 1,439,700 1,545,900 1,494,100 1,408,800 946,800 1,444,400 866,600 1,172,900 (297,400) 1,226,100 862,800 747,600

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Income statement item Description The company
Revenue Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Biogen Inc. revenue increased from Q1 2022 to Q2 2022 but then decreased significantly from Q2 2022 to Q3 2022.
Income from operations The net result for the period of deducting operating expenses from operating revenues. Biogen Inc. income from operations increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Income before income tax (expense) benefit Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Biogen Inc. income before income tax (expense) benefit increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Net income attributable to Biogen Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Biogen Inc. net income attributable to Biogen Inc. increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.